Enhanced Analysis of Leading Longevity Companies as Prospective Investment Targets for Longevity.Capital

Enhanced Analysis of Leading Longevity Companies as Prospective Investment Targets for Longevity.Capital

Coming Soon

“Enhanced Analysis of Leading Longevity Companies as Prospective Investment Targets for Longevity.Capital” is an upcoming proprietary report produced by Aging Analytics Agency under contract by Longevity.Capital, a specialized hybrid investment fund focused on the Longevity sector, who will be using Aging Analytics Agency’s sophisticated multi-layered analytical frameworks to identify the Top-40 Leading Longevity companies within 10 particular sectors specified by Longevity.Capital, to serve as prospective investment targets for their 2020 portfolio, which will be de-risked by diversifying investments across the full scope of Longevity Industry sectors (including Geroscience, P4 Medicine, Regenerative Medicine, AgeTech, Longevity FinTech, Longevity NeuroTech, Longevity FemTech, AI for Longevity, and Biomarkers of Longevity).

The analytical framework developed for this proprietary analytical case-study has been carefully constructed to perform benchmarking across the entire Longevity industry, classifying the full scope of Longevity companies according to levels of advancement. The analytical framework includes both universal metric layters (which are applied equally to all companies), as well as sector-specific metric layers with parameters precisely tuned to the factors particularly relevant for each distinct sector.

Aging Analytics Agency was the first company to apply rigorous and tangible methodologies for assessing the market-readiness of products in the life sciences and biotech space (such as Technology-Readiness Levels, or TRLs), and to establish a validated approach to assessing timelines for clinical translation of Longevity and Preventive Medicine therapies, comparing prospective investment targets using multiple parameters to differentiate levels of maturity, and scientific and technical advantages in an objective manner. For early-stage startups, it applies assessment based on several dozen parameters, whereas for the more advanced leading companies more than 100 factors are considered. 

The higher degree of complexity of the Longevity industry requires novel, more sophisticated approaches to be aligned with the increased complexity of the industry landscape, in order to be capable of deploying relevant industry intelligence and analytics to develop and guide modern and applicable investment strategy for the Longevity sector. Now, it is utilizing its 5+ year experience in these advanced analytics activities to help structure and inform the investment strategy, target portfolio identification and due-diligence processes of Deep Knowledge Ventures’ Longevity-focused subsidiary fund, Longevity.Capital.